#64 ❤️🩹 Healthspan vs Lifespan The Future of Longevity with Cytonics
Most people talk about lifespan. We obsess over how long…
Joey Bose
President & CEO
About Us team
Vision
- Osteoarthritis (OA) affects over 365 million people worldwide — yet Big Pharma has been unable to crack this disease. And we know why.
- We are a clinical-stage biotech company pioneering CYT-108, a genetically engineered therapy that targets the molecular drivers of cartilage breakdown. Inspired by Nature’s blueprint and sharpened by recombinant protein engineering, CYT-108 was designed to overcome pharma’s failed attempts at developing a class of OA therapies designed not to mask symptoms — but to halt disease progression at its source.
- Our vision is simple: to bring forward the world’s first disease-modifying treatment for osteoarthritis. Not with millions in venture capital, but with the collective power of thousands of individual investors who believe in a better future for joint health.
Principles
Nature’s Genius, Perfected
We start with what nature gave us — alpha-2-macroglobulin — and improve upon it. CYT-108 is the result: a more potent, targeted therapy, designed to neutralize the enzymes destroying cartilage.
For the People, By the People
Our innovation is 100% home grown, the result of a handful of resilient individuals whose sheer indefatigability has advanced CYT-108 out of the laboratory and into the clinic without the assistance (or pocketbooks) of pharma partners.
A Grassroots Revolution
We’ve raised over $15 million from more than 6,000 individual investors. No VC. No institutional gatekeepers. Just people, united by a mission to disrupt Big Pharma and reclaim biotech innovation.
Radical Transparency
We’ve earned the trust of our shareholders by hitting our milestones and communicating clearly, frequently, and honestly. We’re building something bigger than a company — we’re building a movement, a new model of biotech innovation that empowers the scientific genius of individuals operating outside of the gravitational fields of Big Pharma and Wall Street.
Executives
Small Team. Big Science. No Gatekeepers.
Cytonics is led by a tight-knit team of scientists, physicians, and entrepreneurs who’ve rejected the traditional biotech playbook. We’re not backed by venture capital. We don’t answer to corporate boards. And we’re not interested in playing by Big Pharma’s rules.
Instead, we’re building a new model — one that puts patients and individual investors at the center of innovation.
Dr. Gaetano Scuderi
Founder and Chief Medical Officer
Alan Liss, PhD
Head of Quality & Manufacturing
Michael Hartwich
Head of Creative Development and Digital Advertising
Advisors
The “OA Dream Team”
Cytonics isn’t just rewriting the playbook on osteoarthritis — we’re throwing out the old rulebook entirely. To do it right, we’ve assembled one of the most accomplished and strategically aligned advisory boards in the industry. These aren’t just experts — they’re believers. Our Medical Advisory Board includes world-class leaders in orthopedics, immunology, and drug development who’ve joined forces with the “little guys” to challenge Big Pharma from the outside.
Ketan Desai MD, PhD
Chief Medical Officer, Levolta Pharmaceuticals
Lachy McLean, MD, PhD
Chief Medical Officer, Genascence Corporation
Mark Schweitzer, MD
Vice President for Health Affairs, Wayne State University
Geoffrey D. Abrams, MD
Associate Professor, Orthopaedic Surgery, Stanford University
Media
Watch
From our blog
News and insights
#63 🌱 Don’t Plant Seeds in a Firestorm: Why Recent Stanford Article Validates Cytonics DMOAD Approach
You may have seen the recent headlines regarding a breakthrough…
#62 🙏 Another Year Full of Gratitude
As the year concludes, Joey Bose reflects on gratitude towards…
Contact Us
Join The Movement
#mc_embed_signup{background:#fff; false;clear:left; font:14px Helvetica,Arial,sans-serif; width: 600px;}
/* Add your own Mailchimp form style overrides in your site stylesheet or in this style block.
We recommend moving this block and the preceding CSS link to the HEAD of your HTML file. */
(function($) {window.fnames = new Array(); window.ftypes = new Array();fnames[0]='EMAIL';ftypes[0]='email';fnames[1]='FNAME';ftypes[1]='text';fnames[3]='MMERGE3';ftypes[3]='phone';fnames[2]='MMERGE2';ftypes[2]='text';}(jQuery));var $mcj = jQuery.noConflict(true);
* indicates required
() -
